RYAM Posts $229M Q3 Loss on $221M Impairments; Temiscaming Idled, Strategic Review Pushed to Q1 2027
RYAM sits 16% above its 52-week low of $5.38.
Summary
RYAM's Q3 loss of $229 million was driven by $221 million of non-cash impairments after tariffs forced the October 3 idling of Temiscaming; adjusted, the loss was $8 million and Adjusted EBITDA rose 30% sequentially to $52 million. The strategic review now targets a Q1 2027 conclusion, with $143 million of liquidity and a 4.0x secured leverage ratio in the meantime.
Key Events · Earnings and Guidance · RYAM
-
Q3 Loss Driven by Non-Cash Impairments
Loss from continuing operations was $229 million, or $(3.40) per diluted share, including $221 million of non-cash impairments; excluding them the loss was $8 million, a 60% sequential improvement.
-
Temiscaming Idled After 50% Tariff
The 50% U.S. tariff on Canadian paperboard effective August 22, 2026 added $2 million of Q3 costs and made production uneconomic; paperboard and high yield pulp operations were economically idled October 3, 2026, with estimated site carrying costs of $2 million to $3 million per month.
-
HPC Earnings Improve Sequentially
High Purity Cellulose income rose to $44 million from $29 million with Adjusted EBITDA of $73 million; total cellulose shipments rose 4% and Cellulose Specialties average price rose 19% year over year to $2,227 per metric ton.
-
Strategic Review Slips to Q1 2027
Management said tariff-related uncertainty at Temiscaming has slowed the process with interested parties and it now targets a conclusion in Q1 2027.
Analysis · RYAM · Manufacturing
The $229 million loss is almost entirely non-cash: $221 million of impairments, including $210 million written off the Paperboard & High Yield Pulp segment after the 50% U.S. tariff on Canadian paperboard made Temiscaming uneconomic and production was idled on October 3. Strip that out and the quarter was a $8 million loss, a 60% sequential improvement, with High Purity Cellulose Adjusted EBITDA of $73 million and consolidated Adjusted EBITDA of $52 million. The real story is the balance sheet and the clock: $143 million of global liquidity ($61 million cash), a 4.0x net secured leverage ratio, and a strategic review now targeted to conclude in Q1 2027 rather than sooner, with Temiscaming carrying $2-3 million per month while idled. Stockholders' equity has fallen to a $35 million deficit, so the sale process is now the main lever for value.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RYAM was trading at $6.24 on NYSE in the Manufacturing sector, with a market capitalization of approximately $467.4M. The 52-week trading range was $5.38 to $11.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.